AbbVie (ABBV) Operating Expenses (2012 - 2026)

AbbVie (ABBV) has 15 years of Operating Expenses data on file, last reported at $11.0 billion in Q1 2026.

• Operating Expenses for Q1 2026 came in at $11.0 billion, up 14.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.5 billion (changed 0.41% YoY), and the FY2025 annual result was $46.1 billion, down 2.36% from the prior year.
• Operating Expenses fell to $11.0 billion in Q1 2026 per ABBV's latest filing, from $12.1 billion in the prior quarter.
• Over five years, Operating Expenses peaked at $16.6 billion in Q4 2024 and troughed at $8.8 billion in Q1 2022.
• A 5-year average of $10.9 billion and a median of $10.5 billion in 2025 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses surged 49.4% in 2024, then fell 27.23% in 2025.
• A 5-year view of Operating Expenses shows it stood at $9.6 billion in 2022, then climbed by 15.46% to $11.1 billion in 2023, then surged by 49.4% to $16.6 billion in 2024, then retreated by 27.23% to $12.1 billion in 2025, then decreased by 8.8% to $11.0 billion in 2026.
• Business Quant data shows ABBV's Operating Expenses at $11.0 billion in Q1 2026, $12.1 billion in Q4 2025, and $13.9 billion in Q3 2025.